0001561921
false
0001561921
2023-08-16
2023-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 16, 2023
TELA Bio, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39130 |
|
45-5320061 |
(State or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
1 Great Valley Parkway, Suite 24
Malvern, Pennsylvania |
|
19355 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (484) 320-2930
Not Applicable
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
TELA |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
On August 16, 2023, TELA Bio, Inc. (the “Company”)
issued a press release announcing the commercial launch of the Company’s OviTex® PRS Long-Term Resorbable product. A copy of
this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are being furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TELA BIO, INC. |
|
|
|
By: |
/s/ Antony Koblish |
|
Name: |
Antony Koblish |
|
Title: |
President, Chief Executive Officer and Director |
Date: August 16, 2023
Exhibit 99.1
TELA Bio Announces U.S. Commercial Launch of
OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
New addition expands reconstruction options
for surgeons and patients
MALVERN, PA.,
August 16, 2023 – TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused
on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration
of the patient's own anatomy, today announced the launch of their OviTex PRS Long-Term Resorbable product. OviTex PRS Long-Term Resorbable
is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement
in plastic and reconstructive surgery. The device is supplied sterile and is intended for one time use.
OviTex PRS Long-Term Resorbable supplements the
Company's existing OviTex PRS portfolio, which includes OviTex PRS Permanent and OviTex PRS Short-Term Resorbable configurations. The
OviTex PRS portfolio is designed to improve outcomes by facilitating functional tissue remodeling while controlling the degree and direction
of stretch. OviTex PRS Long-Term Resorbable enhances the OviTex PRS portfolio with specific design features, including bi-directional
stretch and a fully resorbable, long-term polymer for reinforcement.
“We are excited to offer expanded clinical
utility of the OviTex PRS portfolio to surgeons and patients in plastic and reconstructive surgery,” said Antony Koblish, President
and CEO of TELA Bio. “OviTex PRS Long-Term Resorbable is an important addition to the portfolio as it will allow surgeons to address
clinical indications that require longer term reinforcement while avoiding the use of permanent materials.”
With
6,800+ implantations at over 400 healthcare facilities, OviTex PRS is the only biologic reinforced with interwoven polymer sutures
designed specifically for plastic and reconstructive surgery. This next-generation reinforced biologic is purposefully designed for consistency
in stretch, permeability, and handling while facilitating functional remodeling. The OviTex PRS portfolio provides multiple resorption,
stretch, and shape offerings to meet the unique needs of each patient.
“The OviTex PRS portfolio provides surgeons
with an innovative and effective platform for soft-tissue reconstruction,” said Dr. Howard Langstein, MD, Professor of Plastic
Surgery University of Rochester Medical Center. “My experience with OviTex PRS has been very positive and the addition of a long-term
resorbable reinforcement option further expands the treatment options for my patients.”
To learn more,
visit www.ovitexprs.com .
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage
medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation
and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue
reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic
materials. For more information, visit www.telabio.com.
About OviTex PRS
OviTex PRS Reinforced Tissue Matrix is intended
for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic
and reconstructive surgery. The device is supplied sterile and is intended for one-time use.
Do not use OviTex PRS in patients with a known
sensitivity to materials of ovine (sheep) origin. For prescription use only. For additional important safety information, please see
the OviTex PRS Instructions for Use.
Caution Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such
as "may," "might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan," "intend"
or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the
current beliefs of TELA's management, including with respect to the launch of the OviTex PRS Long-Term Resorbable product. These statements
are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results
and events to differ materially and adversely from those indicated by such forward-looking statements including, among others
the impact to our business from macroeconomic conditions, including the ongoing response to the COVID-19 pandemic, recessionary concerns,
banking instability, and inflationary pressures, potentially impacting our ability to market our products, demand for our products due
to the deferral of elective procedures, the labor and staffing environment in the healthcare industry, disruption in our supply chain,
or pricing pressures concerning our products or the procedures using our products; our ability to achieve or sustain profitability; our
ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully;
that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or
indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical
settings; our ability to enhance our product offerings; development and manufacturing problems; capacity constraints or delays in production
of our products; maintenance of coverage and adequate reimbursement for procedures using our products; product defects or failures.
These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings
with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release,
and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise
after the date of this press release, except as required under applicable law.
Investor Contact
Greg Chodaczek
347-620-7010
ir@telabio.com
Media Contact
Alyson Kuritz
908-892-7149
alyson@0to5.com
v3.23.2
Cover
|
Aug. 16, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 16, 2023
|
Entity File Number |
001-39130
|
Entity Registrant Name |
TELA Bio, Inc.
|
Entity Central Index Key |
0001561921
|
Entity Tax Identification Number |
45-5320061
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1 Great Valley Parkway
|
Entity Address, Address Line Two |
Suite 24
|
Entity Address, City or Town |
Malvern
|
Entity Address, State or Province |
PA
|
Entity Address, Postal Zip Code |
19355
|
City Area Code |
484
|
Local Phone Number |
320-2930
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001 per share
|
Trading Symbol |
TELA
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024